Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
NCT00832507 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2009
- Completion date
- March 31, 2012
- Enrollment
- 162 (actual)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.